- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00655668
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma (EXPECT)
A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®) in Subjects With Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
This is a Phase II, multicenter, single-arm, open-label study of oral lenalidomide monotherapy administered to subjects with relapsed or refractory T-cell lymphoma. This study will be conducted in two phases: a Treatment Phase and a Follow-up Phase.
Subjects who qualify for enrollment into the study will enter the Treatment Phase and receive single-agent lenalidomide 25 mg once daily on Days 1-21 every 28 days (28-day cycles). Subjects may continue participation in the Treatment Phase of the study for a maximum duration of 24 months, or until disease progression or unacceptable adverse events develop.
All subjects who discontinue the Treatment Phase for any reason will continue to be followed until progression of disease or until next lymphoma treatment is given, whichever comes first, during the Follow-up Phase.
Objectives:
Primary:
• To determine the efficacy of lenalidomide monotherapy in relapsed or refractory T-cell Non-Hodgkin's Lymphoma (NHL). Efficacy will be assessed by measuring the response rate, tumor control rate, duration of response, time to progression and progression free survival.
Secondary:
• To evaluate the safety of lenalidomide monotherapy as treatment for subjects with relapsed or refractory T-cell NHL.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australia, 2605
- The Canberra Hospital Building 3, L 2
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 2170
- Cancer Therapy Centre
-
-
Queensland
-
Cairns, Queensland, Australia, 4870
- Clinical Research Unit Cairns Base Hospital
-
Douglas, Queensland, Australia, 4814
- The Townsville Hospital
-
Herston, Queensland, Australia, 4029
- Royal Brisbane & Women's Hospital
-
-
South Australia
-
Ashford, South Australia, Australia, 5035
- Ashford Cancer Centre
-
North Terrace, South Australia, Australia, 5000
- Royal Adelaide Hospital L3 East Wing
-
-
Tasmania
-
Hobart, Tasmania, Australia, 7000
- Royal Hobart Hospital
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Box Hill Hospital, 4th Floor, Clive Ward Centre
-
Clayton, Victoria, Australia, 3168
- Monash Medical Centre
-
East Melbourne, Victoria, Australia, 3002
- Peter Maccallum Cancer Centre
-
Fitzroy, Victoria, Australia, 3065
- St Vincents Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Bruxelles, Belgio, 1200
- Cliniques Universitaires St Luc
-
Bruxelles, Belgio, 1000
- Institute Jules Bordet
-
Leuven, Belgio, 3000
- KUL
-
Ottignies, Belgio, 1340
- Clinique St Pierre
-
Yvoir, Belgio, 5530
- Cliniques Universitaires UCL de Mont-Godinne
-
-
-
-
-
Bordeaux, Francia, 33000
- Polyclinique Bordeaux Nord Aquitaine
-
Clermont-Ferrand, Francia, 63000
- Hôtel Dieu Pavillon Villemur Pasteur
-
Creteil, Francia, 94010
- Hôpital Henri Mondor
-
Dijon, Francia, 21000
- CHU de Dijon
-
Grenoble, Francia, 38043
- Hôpital Michallon
-
La Roche Sur Yon, Francia, 85000
- CHD Les Oudairies
-
Limoges, Francia, 87042
- Chu Dupuytren
-
Metz, Francia, 57000
- Hôpital N.D.de Bon Secours
-
Paris, Francia, 75010
- Hôpital Saint-Louis
-
Paris, Francia, 75015
- Hopital Necker
-
Paris, Francia, 75651
- Hopital de la Pitie Salpetriere
-
Rennes, Francia, 35033
- Chu Rennes Hopital Pontchaillou
-
Rouen, Francia, 76038
- Centre Henri Becquerel
-
Saint Cloud, Francia, 92210
- Centre René Huguenin
-
Toulouse, Francia, 31059
- Hôpital Purpan
-
Valence, Francia, 26953
- Centre Hospitalier
-
-
Cedex 01
-
Nantes, Cedex 01, Francia, 44093
- Chu Hotel Dieu
-
-
Cédex 1
-
Tours, Cédex 1, Francia, 37044
- Hôpital Bretonneau
-
-
Cédex 9
-
Angers, Cédex 9, Francia, 49033
- CHU Hôpital Hôtel Dieu
-
-
Lille
-
Place De Verdun Cedex, Lille, Francia, 59037
- Hopital Claude Huriez
-
-
Montpellier
-
Cedex, Montpellier, Francia, 34295
- Hôpital Lapeyronie
-
-
Pierre-Bénite
-
Lyon Sud, Pierre-Bénite, Francia, 69495
- Centre Hospitalier Lyon Sud
-
-
Rue Morvan Cedex
-
Vandoeuvre Les Nancy, Rue Morvan Cedex, Francia, 54511
- CHRU Hôpitaux de Brabois - Hématologie
-
-
-
-
California
-
Beverly Hills, California, Stati Uniti, 90211-1850
- Tower Cancer Research Foundation
-
-
Kansas
-
Wichita, Kansas, Stati Uniti, 67214
- Cancer Center of Kansas
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Hackensack University Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- Western Pennsylvania Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Must understand and voluntarily sign an informed consent form.
- Must be ≥ 18 years of age at the time of signing the informed consent form.
- Must be able to adhere to the study visit schedule and other protocol requirements.
Biopsy-proven T-cell Non-Hodgkin's Lymphoma, either:
- Peripheral T-cell Lymphoma (PTCL) whatever the subtype, or
- Cutaneous T-cell Lymphoma (CTCL), but only the subtype mycosis fungoides.
- Relapsed or refractory to previous therapy for T-cell Non-Hodgkin's Lymphoma.
- Must have received at least one prior combination chemotherapy regimen. There is no limit on the number of prior therapies.
Exclusion Criteria:
- Cutaneous T-cell Lymphoma of subtype Sézary Syndrome.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Lenalidomide
Open-label, oral lenalidomide monotherapy
|
Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Participants Categorized by Best Response as Determined by Investigator
Lasso di tempo: Up to 24 months
|
Participant response assessed by investigator; criteria by B. Cheson in Journal of Clinical Oncology, 1999 (see article for more detail):
|
Up to 24 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Duration of Response
Lasso di tempo: Up to 24 months
|
Kaplan-Meier Estimate of duration of response calculated as the time from first computed tomography (CT) Scan or magnetic resonance imaging (MRI) that demonstrates at least a partial response to the first documentation of disease progression, including death due to Non-Hodgkin's Lymphoma.
|
Up to 24 months
|
Time-to-Progression
Lasso di tempo: Up to 24 months
|
Kaplan-Meier estimate of time-to-progression is calculated as the time from the start of study drug therapy to the first documentation of progressive disease.
|
Up to 24 months
|
Progression-Free Survival
Lasso di tempo: Up to 24 months
|
Kaplan-Meier estimate of progression-free survival is defined as the start of study drug therapy to the first observation of disease progression or death due to any cause.
|
Up to 24 months
|
Safety
Lasso di tempo: Up to 24 months
|
Summary of Treatment-Emergent Events in Safety Population (participants with at least one dose of study drug).
Events assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 3: Following is the scale: Grade 1=Mild Adverse Event (AE), Grade 2=Moderate AE, Grade 3=Severe and Undesirable AE, Grade 4=Life-threatening or Disabling AE, and Grade 5=Death Related to AE.)
|
Up to 24 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Kenichi Takeshita, MD, Celgene Corporation
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Neoplasie
- Malattie linfoproliferative
- Malattie linfatiche
- Disturbi immunoproliferativi
- Linfoma
- Linfoma non Hodgkin
- Linfoma, cellule T
- Effetti fisiologici delle droghe
- Agenti antineoplastici
- Fattori immunologici
- Inibitori dell'angiogenesi
- Agenti di modulazione dell'angiogenesi
- Sostanze per la crescita
- Inibitori della crescita
- Lenalidomide
Altri numeri di identificazione dello studio
- CC-5013-TCL-001
- 2007-002171-13 (Numero EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Linfoma non Hodgkin a cellule T
-
National Cancer Centre, SingaporeTerminatoLINFOMA EXTRANODALE NK-T-CELLSingapore
Prove cliniche su Lenalidomide
-
Arbeitsgemeinschaft medikamentoese TumortherapieCelgene CorporationSconosciutoLeucemia Mielomonocitica CronicaAustria
-
University Hopsital Schleswig Holstein Campus LübeckReclutamentoMieloma multiplo di nuova diagnosiGermania